We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
The current KEYBF market cap is 0. The company's latest EPS is CNY and P/E is N/A.
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| CNY (元) | CNY (元) | CNY (元) | CNY (元) | CNY (元) | |
| Total Revenue | 0 | 0 | 110.27M | 100.06M | 354.1M |
| Operating Income | -67.14M | -135.5M | -353.5M | -488.58M | -438.36M |
| Net Income | -167.51M | -818.58M | -3.89B | -308.12M | -359.36M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| CNY (元) | CNY (元) | CNY (元) | CNY (元) | CNY (元) | |
| Total Assets | 658.58M | 529.95M | 3.93B | 3.93B | 3.88B |
| Total Liabilities | 934.53M | 1.62B | 289.07M | 593.1M | 896.11M |
| Total Equity | -275.96M | -1.09B | 3.65B | 3.34B | 2.99B |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| CNY (元) | CNY (元) | CNY (元) | CNY (元) | CNY (元) | |
| Operating | -68.38M | -119.36M | -214.64M | -401.93M | -303.62M |
| Investing | -58.02M | -113.07M | -2.04B | -645.59M | 468.2M |
| Financing | 505.07M | 7.4M | 3.64B | -8.06M | 72.13M |
| Market Cap | 0 |
| Price to Earnings Ratio | N/A |
| Price to Sales Ratio | 0 |
| Price to Cash Ratio | 0 |
| Price to Book Ratio | 0 |
| Dividend Yield | - |
| Shares Outstanding | 279.74M |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 0 |
| 52 Week Change | - |
| 52 Week High | - |
| 52 Week Low | - |
| Spread (Intraday) | 0 (0%) |
| Company Name | KeyMed Biosciences Inc (PK) |
| Address |
floor 4 grand cayman KY1-9010 |
| Website | https://www.keymedbio.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
